Challenges for Clinical Implementation of Genomic Medicine by Lyon, Gholson J.
Challenges	  for	  Clinical	  Implementa3on	  of	  
Genomic	  Medicine	  
	  
Gholson	  J.	  Lyon,	  M.D.	  Ph.D.	  
	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
  
Barry	  Moore	  
Alan	  Rope	  
Jeﬀrey	  J	  Swensen	  
Lynn	  Jorde	  
Mark	  Yandell	  
	  
Acknowledgments 
our	  study	  families	  
and	  many	  others	  
Reid	  Robison	  
	  
Jason	  O’Rawe	  
Yiyang	  Wu	  
Han	  Fang	  
Max	  Doerfel	  
Michael	  Schatz	  
Giuseppe	  Narzisi	  
Kai	  Wang	  
David	  MiMelman	  
	  
MarOn	  Reese	  
Edward	  Kiruluta	  
Tina	  Hambuch	  
Erica	  Davis	  
Dawn	  Barry	  
Thomas	  Arnesen	  
Nathalie	  Reuter	  
Line	  Myklebust	  
	  
Ghent,	  Belgium	  
Petra	  Van	  Damme	  
Kris	  Gevaert	  
	  
Han	  Fang	  
Jason	  O’Rawe	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yiyang	  Wu	  
Max	  Doerfel	  
Conﬂicts	  of	  Interest	  
	  
Advisory	  Boards	  
Rare	  Diseases	  
One	  family	  in	  Utah	  with	  a	  very	  rare	  disease.	  
I
II 
III 
1 +/ 2 +/mt 
1 mt/ 
1
2 +/mt 
2 +/ 3 +/+ 4 mt/ 
3  +/mt 
5 7 mt/ 
4 5 +/mt 6 7 +/+ 8 +/ 
SB 
6 mt/ 
An	  unrelated	  second	  family	  was	  also	  
idenOﬁed,	  due	  to	  sharing	  the	  same	  
genotype,	  i.e.	  the	  same	  mutaOon.	  
II-1 III-2 
Ogden Syndrome, in honor of where the first family 
lives, in Ogden, Utah 
Big	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  learn	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Challenges	  for	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  Implementa3on	  of	  Genomic	  Medicine	  
	  
Major	  barriers	  to	  the	  widespread	  implementa3on	  
of	  genomic	  medicine	  in	  the	  clinic.	  	  
•  Limits	  of	  our	  current	  technology	  &	  knowledge	  
•  Lack	  of	  public	  educaOon	  	  
•  Lack	  of	  physician	  knowledge	  about	  geneOcs	  
•  Apathy	  on	  the	  part	  of	  the	  populace	  in	  terms	  of	  
prevenOve	  eﬀorts	  	  
•  Reluctance	  of	  insurance	  companies	  &	  
governments	  to	  pay	  for	  geneOc	  tesOng	  
•  Focus	  in	  our	  society	  on	  treatment,	  not	  on	  early	  
diagnosis	  and	  prevenOon	  
•  Privacy	  concerns	  
	  
“It	  is	  perhaps	  naive	  to	  expect	  that	  these	  obstacles	  can	  be	  overcome	  
within	  the	  next	  20	  years,	  and	  it	  may	  very	  well	  be	  the	  case	  that	  there	  
might	  be	  a	  50-­‐year	  Ome	  horizon	  on	  the	  secure	  implementaOon	  of	  clinical	  
genomics	  and	  individualized	  medicine.	  We	  certainly	  hope	  that	  every	  
newborn	  will	  have	  the	  vast	  majority	  of	  their	  genome	  sequenced	  and	  
digitally	  available	  by	  the	  year	  2062”.	  	  
	  
AnalyOc	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•  Sequencing	  “clinical-­‐grade	  genomes”	  
•  BioinformaOcs	  analysis	  
	  
Clinical	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Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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A B S T R A C T
Purpose
Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the
performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a
representative clinical sample.
Methods
Patients referred for clinical BRCA1/2 testing from 2002 to 2012 were invited to donate a research
blood sample. Samples were frozen at !80° C, and DNA was extracted from them after 1 to 10
years. The entire coding region, exon-intron boundaries, and all known pathogenic variants in other
regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable
results were disclosed to participants.
Results
In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline
BRCA1/2mutations. BRCA1/2 analysis was fully concordant with prior testing. Sixteen pathogenic
variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4
among 141 women without BRCA1/2 mutations. Fourteen participants carried 15 pathogenic
variants, warranting a possible change in care; they were invited for targeted screening
recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy.
Participants carried an average of 2.1 variants of uncertain significance among 42 genes.
Conclusion
Among women testing negative for BRCA1/2 mutations, multiple-gene sequencing identified 16
potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15
(10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early
detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance
of identified mutations and determine clinical utility. However, these results suggest that
multiple-gene sequencing may benefit appropriately selected patients.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Clinical genetic testing for cancer-risk assessment
has become widespread over the last two decades,
with evidence-based testing guidelines for heredi-
tary breast and ovarian cancer (BRCA1 andBRCA2;
BRCA1/2), Lynch syndrome (MLH1, MSH2,
MSH6, PMS2, and EPCAM), familial adenomatous
polyposis (APC), hereditary diffuse gastric cancer
(CDH1), Li-Fraumeni syndrome (TP53), Cowden’s
syndrome (PTEN), and a few other conditions.1-4
Cancer genetic counseling and risk-reducing in-
terventions have accordingly been developed for
high penetrance, autosomal dominant conditions.
Most of these interventions, especially prophylactic
surgery, are excessive for carriers of mutations that
have uncertain pathogenicity.5-7 Recently, next-
generation technology has enabled massively paral-
lel sequencing at low cost, and panels of multiple
cancer-associated genes are newly available for clin-
ical use.8,9
Despite these advances in technology, a critical
knowledgedeficit remains about the clinical valueof
multiple-gene panels for cancer susceptibility. Ma-
jor questions include howmany andwhich genes to
sequence, whether results are sufficiently under-
stood to guide intervention, and how best to coun-
sel patients about variants of low or moderate
penetrance.8,10-12 We designed a customized germ-
line sequencing panel of 42 cancer-associated genes
and evaluated its information yield among women
referred for clinical evaluation of hereditary breast
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Sequencing	  of	  42	  genes,	  captured	  with	  Agilent	  custom	  capture	  
The	  enOre	  coding	  region,	  exon-­‐intron	  boundaries	  (±	  10	  bp),	  and	  other	  regions	  were	  
targeted	  and	  captured	  using	  Agilent	  SureSelect	  custom	  RNA	  probes	  and	  Integrated	  
DNA	  Technologies	  xGen	  Lockdown	  custom	  DNA	  probes.	  	  
	  
QuanOﬁed	  libraries	  were	  sequenced	  on	  the	  Illumina	  MiSeq	  plaporm	  using	  the	  2	  x	  151	  
bp	  conﬁguraOon	  to	  at	  least	  400x	  average	  coverage.	  BioinformaOcs	  and	  data	  quality	  
control	  followed	  the	  Genome	  Analysis	  Toolkit	  best-­‐pracOces,	  with	  addiOonal	  
algorithms	  to	  detect	  larger	  inserOons,	  deleOons,	  and	  duplicaOons.	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Interrogating human genome from single-codon 
resolution to large structural events with WGS 
Fang	  et.al	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GATKv3 - HC/
Joint Gentotyping
FreeBayes
BWA-MEM NovoAlign
Scalpel*
Whole Genome Sequencing (mean coverage=40x) 2.5 M Genotyping Array
ERDS/
Lumpy
PennCNVGenome 
Studio
INDELs
SNPs
&
INDELs
SNPs
&
INDELs
CNVs SNPs CNVs
Sequencing 
+ 
Genotyping
WGS QC
+
Alignment
Assembly
+
Variant Calling
Raw Variants
Pool
High Quality
 Variants
Ready-to-Use
VAAST 2.0 CADD Gold Helix SVS ANNOVAR
In-house 
Filtering
MiSeq
Resequencing
Pedigree-aware
Variant Calling
RepeatSeq/
LobSTR
SangerGenotype
Refinement
Variant
Filtering
Variant
Prioritization
& Annotation
Ingenuity
Variant Analysis Pipeline for Whole Genome Sequencing Data
Omicia Opal PharmGKB
Diagnosis
Support
Tute Genomics
* Scalpel (In press)  http://schatzlab.cshl.edu/
Narzisi et.al (Accepted in Nat. Methods)	  
Developing the best INDEL caller, with a large validation of 
1400 INDELs 
77%	  PPV 
50% PPV 
22% PPV 
Scalpel 
SOAPindel 
HapCaller v2.4 
Narzisi et.al (Accepted in Nat. Methods)	  
There	  are	  recent	  improvements	  with	  GATK	  v3.0	  with	  
45%	  PPV,	  but	  Scalpel	  sOll	  out-­‐performs	  this.	  
Extending Scalpel with comparisons of WGS & 
WES data 
•  WGS and WES were performed on 8 samples. 
•  Illumina HiSeq 2000 platform, paired-end 100 bp reads. 
•  Exome Capture Kit: NimbleGen SeqCap EZ Exome v2.0 
capture reagent, representing 36.0 Mb (approximately 
300,000 exons) of the human genome (hg19 build). 
•  WGS: Mean coverage= ~70x, ~95% > 20x  
•  WES: Mean coverage= ~320x, ~75% > 20x 
•  PCR duplicates were removed from the alignment.  
•  Inspected 25bp upstream and downstream around the 
loci of interest. 
1051 4201633
WGS WES
991 3261617
WGS WES
Mean concordance (8 samples) between WGS and WES data. 
If keeping only regions in both data by requiring at least 1 read, the mean concordance 
rates increased to 62.1% (exact match) and 65.6% (positions based), respectively.  
33.9% 52.6% 13.5% 33.7% 55.1% 11.1% 
Exact match	   Position Based	  
High Confidence INDELs 
WGS yielded more “higher quality” INDELs, relative to WES.  
Classification of call sets with previous validation data: 
Low Error Rate:           Coverage(alternative allele) >10 reads or χ2 <4 
High Error Rate:          Coverage(alternative allele) <10 reads and χ2 >10.84 
Moderate Error Rate:  Do not fall into the above two categories. 
 
Note: The number on top of a category represents the mean number of INDELs in that category. 
Figure	  is	  removed	  for	  posOng.	  
Majority of “lower quality” INDELs are homopolymer A/T related. 
Classification of call sets with previous validation data: 
Low Error Rate:           Coverage(alternative allele) >10 reads or χ2 <4 
High Error Rate:          Coverage(alternative allele) <10 reads and χ2 >10.84 
Moderate Error Rate:  Do not fall into the above two categories. 
 
Note: The number on top of a category represents the mean number of INDELs in that category. 
Figure	  is	  removed	  for	  posOng.	  
Comparisons of PCR-Free & With-PCR data 
•  Illumina HiSeq 2000 platform, paired-end 100 bp reads. 
•  PCR-Free: Mean coverage= ~50x  
•  With-PCR: Mean coverage= ~50x after removing PCR 
duplicates 
692 3952684
With−PCR PCR−Free
71.2% 
538 3102651
With−PCR PCR−Free
18.3% 10.5% 75.8% 8.8% 15.4%	  
Exact match	   Position Based	  
High Confidence INDELs 
With-PCR yielded more “lower quality” INDELs, relative to 
PCR-Free. 	  
Classification of call sets with previous validation data: 
Low Error Rate:           Coverage(alternative allele) >10 reads or χ2 <4 
High Error Rate:          Coverage(alternative allele) <10 reads and χ2 >10.84 
Moderate Error Rate:  Do not fall into the above two categories. 
 
Note: The number on top of a category represents the mean number of INDELs in that category. 
Figure	  is	  removed	  for	  posOng.	  
Most of these “lower quality” INDELs are homopolymer A/T 
related.	  
Classification of call sets with previous validation data: 
Low Error Rate:           Coverage(alternative allele) >10 reads or χ2 <4 
High Error Rate:          Coverage(alternative allele) <10 reads and χ2 >10.84 
Moderate Error Rate:  Do not fall into the above two categories. 
 
Note: The number on top of a category represents the mean number of INDELs in that category. 
Figure	  is	  removed	  for	  posOng.	  
Margulies et.al (2011) 
Previous works tried to understand coverage requirement for 
SNP calling. But how deep is deep enough for INDEL calling? 
Recommend mean coverage of 60X for personal genome 
sequencing to achieve high accuracy INDEL detection 
Figure	  is	  removed	  for	  posOng.	  
Detection of heterozygous INDELs requires higher coverage; 
reaffirm the recommendation of 60X mean coverage 
Figure	  is	  removed	  for	  posOng.	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One	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  in	  Utah	  with	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  very	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Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
preMy	  much	  ALL	  mutaOons	  in	  humans,	  as	  we	  
have	  not	  systemaOcally	  sequenced	  or	  
karyotyped	  any	  geneOc	  alteraOon	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people.	  
	  
Categorical	  Thinking	  Misses	  Complexity	  
A	  conceptual	  model	  of	  genotype-­‐phenotype	  correla3ons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  Ome,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctuaOons.	  	  	  
Time	  
Environment	  
Phenotypic	  
Spectrum	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“There	  are	  ~12	  billion	  nucleoOdes	  in	  every	  cell	  of	  the	  human	  body,	  and	  there	  are	  
~25-­‐100	  trillion	  cells	  in	  each	  human	  body.	  Given	  somaOc	  mosaicism,	  epigeneOc	  
changes	  and	  environmental	  diﬀerences,	  no	  two	  human	  beings	  are	  the	  same,	  
parOcularly	  as	  there	  are	  only	  ~7	  billion	  people	  on	  the	  planet”.	  	  

REPORT
XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.
Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because
unrelated probands with comparable phenotypes can
bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, or
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Guidelines for investigating causality of
sequence variants in human disease
D. G.MacArthur1,2, T. A.Manolio3, D. P. Dimmock4, H. L. Rehm5,6, J. Shendure7, G. R. Abecasis8, D. R. Adams9,10, R. B. Altman11,
S. E. Antonarakis12,13, E. A. Ashley14, J. C. Barrett15, L. G. Biesecker16, D. F. Conrad17, G. M. Cooper18, N. J. Cox19, M. J. Daly1,2,
M. B. Gerstein20,21, D. B. Goldstein22, J. N. Hirschhorn2,23, S. M. Leal24, L. A. Pennacchio25,26, J. A. Stamatoyannopoulos27,
S. R. Sunyaev28,29, D. Valle30, B. F. Voight31, W. Winckler2{ & C. Gunter18{
The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence
variants from the many potentially functional variants present in any human genome are urgently needed. Without
rigorous standards we risk an acceleration of false-positive reports of causality, which would impede the translation of
genomic research findings into the clinical diagnostic setting and hinder biological understanding of disease. Here we
discuss the key challenges of assessing sequence variants in human disease, integrating both gene-level and variant-
level support for causality. We propose guidelines for summarizing confidence in variant pathogenicity and highlight
several areas that require further resource development.
H igh-throughput sequencing approaches can generate detailedcatalogues of genetic variation in both disease patients and thegeneral population. However, for these technologies to have the
greatest medical impact we must be able to separate genuine disease-
causing or disease-associated genetic variants reliably from the broader
background of variants present in all human genomes that are rare, po-
tentially functional, but not actually pathogenic (Box 1) for the disease
or phenotype under investigation.
Many, but unfortunately not all, variants that have been causally
associated with rare and common genetic disorders represent robust and
correct conclusions. False assignments of pathogenicity can have severe
consequences for patients, resulting in incorrect prognostic, therapeutic
or reproductive advice, and for the research enterprise, resulting in mis-
allocation of resources for basic and therapeutic research. Unfortunately,
although the vast majority of genes reported as causally linked to mono-
genicdiseases are truepositives, false assignmentsof causality at the variant
level are a substantial issue. One recent analysis of 406 published severe
disease mutations observed in 104 newly sequenced individuals reported
that 122 (27%) of these were either common polymorphisms or lacked
direct evidence for pathogenicity1. Other studies have identified numer-
ous alleged severe-disease-causing variants in the genomes of population
controls2,3. In other cases, well-powered follow-up studies of high-profile
reported mutations have cast serious doubts on initial reports assigning
disease causality to sequence variants4,5, but the vast majority of false-
positive findings probably remain undetected. As the volume of patient
sequencing data increases it is critical that candidate variants are sub-
jected to rigorous evaluation to prevent furthermisannotation of the path-
ogenicity of variants in public databases.
This paper describes the challenges in reliably investigating the role
of sequence variants in human disease, and approaches to evaluate the
evidence supporting variant causality. It represents the conclusions of a
working group of experts in genomic research, analysis and clinical diag-
nostic sequencing convenedby theUSNationalHumanGenomeResearch
Institute.
We focus on the application of genome-scale approaches to investi-
gating rare germline variants, defined here as variants with aminor allele
frequency of,1%. Our recommendations aremost relevant for variants
with relatively large effects on disease risk. Our intended scope encom-
passes the vast majority of variants implicated in severe monogenic dis-
eases as well as rare, large-effect risk variants in complex disease6, but
excludes the common, small-effect variants typically identified by gen-
ome-wide association studies of complex traits7.
Unambiguous assignment of disease causality for sequence variants is
often impossible, particularly for the very low-frequency variants under-
lying many cases of rare, severe diseases. Consequently, we refer in this
manuscript to the concept of implicating a gene or sequence variant: that
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Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa3entsLikeMe	  
Major	  barriers	  to	  the	  widespread	  implementa3on	  
of	  genomic	  medicine	  in	  the	  clinic.	  	  
•  Limits	  of	  our	  current	  technology	  &	  knowledge	  
•  Lack	  of	  public	  educaOon	  	  
•  Lack	  of	  physician	  knowledge	  about	  geneOcs	  
•  Apathy	  on	  the	  part	  of	  the	  populace	  in	  terms	  of	  
prevenOve	  eﬀorts	  	  
•  Reluctance	  of	  insurance	  companies	  &	  
governments	  to	  pay	  for	  geneOc	  tesOng	  
•  Focus	  in	  our	  society	  on	  treatment,	  not	  on	  early	  
diagnosis	  and	  prevenOon	  
•  Privacy	  concerns	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“If you sequence people’s exomes you’re going to find stuﬀ,” said Gholson Lyon, 
a physician and researcher previously at the University of Utah, now at Cold 
Spring Harbor Laboratory.
As part of his research, Dr. Lyon worked with a family in Ogden, Utah. Over 
two generations, four boys had died from an unknown disease with a distinct 
combination of symptoms—an aged appearance, facial abnormalities, and devel-
opmental delay. Dr. Lyon sought to identify the genetic cause of this disease, and 
collected blood samples from 12 family members who had signed consent forms. 
The family members understood these forms to mean that they would have access 
to their results.
Dr. Lyon conducted exon capture and sequencing of the X chromosome—a 
process that analyzes specific regions of the X chromosome and is a less expensive 
alternative to whole genome sequencing—to analyze the blood samples. Dr. 
Lyon and his colleagues identified a genetic mutation, and named the disease 
Ogden Syndrome after the family’s hometown.
After Dr. Lyon and his team identified the genetic basis of Ogden Syndrome, 
one of the family members contacted him. This young mother of one daughter 
had submitted a blood sample for Dr. Lyon’s research. She had not been preg-
nant at the time, but was now four months pregnant with her second child. 
She knew that she was carrying a boy and wanted to know if she was a carrier 
of the mutation. She wanted to be able to mentally and emotionally prepare 
herself and her family.
By reexamining his research data, Dr. Lyon was able to see that the expectant 
mother was a carrier of Ogden Syndrome. This meant that her son had a 50 
percent chance of being born with the disease. Dr. Lyon could not, however, 
legally share this important information with the family because he had conducted 
the original sequencing in a research laboratory that had not satisfied federally 
mandated standards designed to ensure the accuracy of clinical genetic results.
Instead, Dr. Lyon worked to have the mutation validated at a laboratory that 
satisfied those federal standards; this involved overcoming substantial bureau-
cratic hurdles and other obstacles that held up the process. During this time, 
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the baby boy was born and died of Ogden Syndrome at four months of age. 
While knowing the results would not have changed the outcome, Dr. Lyon feels 
he should have been able to do more for the family.
Dr. Lyon has become an outspoken advocate for conducting whole genome 
sequencing in laboratories that satisfy the federal standards so that researchers 
can return results to participants, if appropriate. Dr. Lyon wants clear guid-
ance for laboratories conducting genetic research and clear language in consent 
forms that clarifies the results that participants should expect to have returned 
from the researchers.
Realizing the promise of whole genome sequencing requires widespread 
public participation and individual willingness to share genomic data and 
relevant medical information. This requires public trust that any whole 
genome sequence data shared by individuals with researchers and clinicians 
will be adequately protected. Individuals must trust that eir whole genome 
sequence d ta will not be either i tentionally or i advert ntly disclosed or 
misused. Current U.S. g vernance and oversight f genetic and genomic 
data, however, do not fully protect i dividuals from the risks associated with 
sharing their whole genome sequence data and information. 
The Genetic Information Nondiscrimination Act of 2008 (GINA) is the 
leading federal protection of genetic information, but it oﬀers only prohibi-
tion of genetic discrimination in health insurance and employment. GINA 
does not regulate access, security, and disclosure of genetic or whole genome 
sequence information across all potential users, nor does it protect against 
discrimination in other contexts. U.S. state laws on genetic information 
vary greatly in their protections of individuals, and they also fail to provide 
uniform privacy protections. In an era in which whole genome sequence data 
are increasingly stored and shared using biorepositories and databases, there 
is little to no systematic oversight of these systems. 
Ethical Principles
Laws and regulations cannot do all of the work necessary to provide suﬃcient 
privacy protections for whole genome sequence data. Individuals who obtain 
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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. That said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing eﬀorts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain ﬁndings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
speciﬁc variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular ﬁndings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneﬁcial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal deﬁnition is really quite
clear, as CLIA speciﬁcally states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are speciﬁ-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difﬁculties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certiﬁ-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is deﬁned by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certiﬁed, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The beneﬁts of enacting such a split model could be substantial,
and we believe they could be gained without signiﬁcantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certiﬁed genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and veriﬁcation of performance speciﬁcations
4) Maintenance and function checks
5) Calibration and calibration veriﬁcation procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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1.	  Sample	  CollecOon	  and	  handling	  
	  
	  
2.	  Sequencing/AnalyOcs	  
	  
	  
3.	  InterpretaOon	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris3cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer3ﬁed,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra3on.	  If	  you	  have	  
any	  ques3ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa3on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene3c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	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ABSTRACT
Background. In recent years, there has been an explosion in the number of technical
and medical diagnostic platforms being developed. This has greatly improved our
ability to more accurately, and more comprehensively, explore and characterize
human biological systems on the individual level. Large quantities of biomedical
data are now being generated and archived in many separate research and clinical
activities, but there exists a paucity of studies that integrate the areas of clinical
neuropsychiatry, personal genomics and brain-machine interfaces.
Methods. A single person with severe mental illness was implanted with the
Medtronic Reclaim® Deep Brain Stimulation (DBS) Therapy device for Obsessive
Compulsive Disorder (OCD), targeting his nucleus accumbens/anterior limb of the
internal capsule. Programming of the device and psychiatric assessments occurred
in an outpatient setting for over two years. His genome was sequenced and vari-
ants were detected in the Illumina Whole Genome Sequencing Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory.
Results. We report here the detailed phenotypic characterization, clinical-grade
whole genome sequencing (WGS), and two-year outcome of a man with severe
OCD treated with DBS. Since implantation, this man has reported steady improve-
ment, highlighted by a steady decline in his Yale-Brown Obsessive Compulsive Scale
(YBOCS) score from⇠38 to a score of⇠25. A rechargeable Activa RC neurostimula-
tor battery has been of major benefit in terms of facilitating a degree of stability and
control over the stimulation. His psychiatric symptoms reliably worsen within hours
of the battery becoming depleted, thus providing confirmatory evidence for the
eYcacy of DBS for OCD in this person.WGS revealed that he is a heterozygote for the
p.Val66Met variant in BDNF, encoding a member of the nerve growth factor family,
and which has been found to predispose carriers to various psychiatric illnesses.
He carries the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR)
and the p.Asp7Asn allele in ChAT, encoding choline O-acetyltransferase, with both
alleles having been shown to confer an elevated susceptibility to psychoses. We have
found thousands of other variants in his genome, including pharmacogenetic and
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activities, but there exists a paucity of studies that integrate the areas of clinical
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Compulsive Disorder (OCD), targeting his nucleus accumbens/anterior limb of the
internal capsule. Programming of the device and psychiatric assessments occurred
in an outpatient setting for over two years. His genome was sequenced and vari-
ants were detected in the Illumina Whole Genome Sequencing Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory.
Results. We report here the detailed phenotypic characterization, clinical-grade
whole genome sequencing (WGS), and two-year outcome of a man with severe
OCD treated with DBS. Since implantation, this man has reported steady improve-
ment, highlighted by a steady decline in his Yale-Brown Obsessive Compulsive Scale
(YBOCS) score from⇠38 to a score of⇠25. A rechargeable Activa RC neurostimula-
tor battery has been of major benefit in terms of facilitating a degree of stability and
control over the stimulation. His psychiatric symptoms reliably worsen within hours
of the battery becoming depleted, thus providing confirmatory evidence for the
eYcacy of DBS for OCD in this person.WGS revealed that he is a heterozygote for the
p.Val66Met variant in BDNF, encoding a member of the nerve growth factor family,
and which has been found to predispose carriers to various psychiatric illnesses.
He carries the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR)
and the p.Asp7Asn allele in ChAT, encoding choline O-acetyltransferase, with both
alleles having been shown to confer an elevated susceptibility to psychoses. We have
found thousands of other variants in his genome, including pharmacogenetic and
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
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Commercial analysis platforms for genomic data 
No	  rare	  variants	  or	  CNVs	  with	  high	  biological	  eﬀect	  as	  related	  to	  
mental	  illness.	  	  
	  
Here	  are	  just	  3	  of	  dozens	  of	  common	  SNVs	  in	  this	  person	  that	  
have	  been	  implicated	  in	  the	  literature	  as	  predisposing	  to	  mental	  
illness.	  
Table 1 A summary of three clinically relevant alleles found in the sequencing results of MA. Variations in MTHFR, BDNF, and ChAT were
found to be of potential clinical relevance for this person as they are all implicated in contributing to the susceptibility and development of many
neuropsychiatric disorders that resemble those present within MA. A brief summary of the characteristics of each variation is shown, including the
gene name, genomic coordinates, amino acid change, zygosity, variation type, estimated population frequency and putative clinical significance.
Gene
name
Genomic
coordinates
Amino acid
change
Zygosity Variation
type
Population
frequency
Clinical significance
MTHFR chr1: 11854476 Glu> Ala heterozygous non-synon T:77% G:23% Susceptibility to psychoses, schizophrenia
occlusive vascular disease, neural tube defects,
colon cancer, acute leukemia, and methylenetetra-
hydrofolate reductase deficiency
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% Susceptibility to OCD, psychosis, and diminished
response to exposure therapy
CHAT chr10: 50824117 Asp> Asn heterozygous non-synon G:85% A:15% Susceptibility to schizophrenia and other psy-
chopathological disorders.
be given the opportunity, like with many other traditional medical tests, to obtain “second
opinions”. For this to be possible, one must accurately describe the contents of short-read
sequencing data in terms of the existing electronic medical health standards, so that these
data can be incorporated into an electronic medical health record. Accurately describing
the contents of next generation sequencing (NGS) results is particularly critical for
clinical analysis of genomic data. However, genomics and medicine use diVerent and
often incompatible terminologies and standards to describe sequence variants and their
functional eVects. In our eVorts to treat this one person with severe mental illness, we
have implemented the GVFclin format for the variants that were discovered during the
sequencing of his whole genome (see File S12). We hope to eventually incorporate his
genetic data into his electronic health record if and when the VistA health information
system (HIS) (Conn, 2011; Protti & Groen, 2008; Kuzmak & DayhoV, 1998; Brown et al.,
2003) is upgraded to allow entry of such data.We did already counsel MA regarding several
genetic variants that may be clinically relevant to predisposing him to his psychiatric
disorder (Biesecker & Peay, 2013).
Returning genetic results
There is considerable controversy in the field of medical genetics concerning the extent of
return of genetic results to people, particularly in the context of “secondary”, “unrelated”,
“unanticipated” or “incidental” findings stemming from new high-throughput sequencing
techniques (Lyon, 2012c). Some people have concerns regarding the clinical utility
of much of the data, and in response have advocated for selectively restricting the
returnable medical content. One such set of recommendations has been provided by
the American College ofMedical Genetics which recently released guidelines in which they
recommended the “return of secondary findings” for 57 genes, without detailed guidance
for the rest of the genome (Green et al., 2013). These types of recommendations take
a more paternalistic approach in returning test results to people, and generally involve
a deciding body of people that can range in size from a single medical practitioner to
a committee of experts. We believe that anyone should be able to access and manage
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PharmacogeneOcs	  
u  MA	  is	  homozygous	  for	  a	  p.Ile359Leu	  change	  in	  CYP2C9,	  and	  this	  variant	  
has	  been	  linked	  to	  a	  reducOon	  in	  the	  enzymaOc	  acOvity	  of	  CYP2C9,	  a	  
member	  of	  the	  cytochrome	  P450	  superfamily	  of	  enzymes.	  	  
	  
u  FluoxeOne	  is	  commonly	  used	  in	  the	  treatment	  of	  OCD..	  	  
u  CYP2C9	  acts	  to	  convert	  ﬂuoxeOne	  to	  R-­‐norﬂuoxeOne,	  and	  so	  MA	  may	  not	  
be	  able	  to	  adequately	  biotransform	  ﬂuoxeOne.	  
u  It	  is	  notable	  that	  MA	  had	  no	  response	  to	  an	  80	  mg	  daily	  dose	  of	  ﬂuoxeOne.	  
u  However,	  CYP2C9	  does	  not	  play	  a	  rate-­‐limiOng	  role	  for	  other	  SSRIs	  or	  
clomipramine	  
Clinical	  Validity	  with	  Worldwide	  
Human	  GeneOc	  VariaOon	  “database”?	  
Pa3entsLikeMe	  
100,000	  Bri3sh	  Genomes	  
Major	  barriers	  to	  the	  widespread	  implementa3on	  
of	  genomic	  medicine	  in	  the	  clinic.	  	  
•  Limits	  of	  our	  current	  technology	  &	  knowledge	  
•  Lack	  of	  public	  educaOon	  	  
•  Lack	  of	  physician	  knowledge	  about	  geneOcs	  
•  Apathy	  on	  the	  part	  of	  the	  populace	  in	  terms	  of	  
prevenOve	  eﬀorts	  	  
•  Reluctance	  of	  insurance	  companies	  &	  
governments	  to	  pay	  for	  geneOc	  tesOng	  
•  Focus	  in	  our	  society	  on	  treatment,	  not	  on	  early	  
diagnosis	  and	  prevenOon	  
•  Privacy	  concerns	  
	  
Summary	  
•  Ancestry,	  i.e.	  geneOc	  background,	  maMers.	  
•  CollecOvely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  
parOcipants	  and	  others.	  
•  We	  need	  to	  sequence	  accurate	  whole	  
genomes	  of	  large	  pedigrees,	  and	  then	  
construct	  super-­‐family	  structures.	  
	  
